Gregor Kawaletz featured on Making It in Manufacturing podcast

• Our CEO has participated in an interview for the Making It in Manufacturing podcast, recorded during CPHI 2025 Frankfurt.
• Gregor shares his perspective from the first month as CEO and reflects on what it takes to lead a publicly listed CDMO through a shifting global market.

When an experienced captain is at the helm, the crew can remain confident of a safe voyage even during a storm. Gregor Kawaletz has brought more to Mabion than just his professional network. Through his business commitment and hands-on approach, he embodies leadership in action. Working on the front line, he meets with clients daily to support the advancement of biopharma projects.

Key topics include:

• Mabion’s growth priorities
• Confidence-building across the pipeline
• Evolving business model designed to support long-term value creation

Gregor also discusses the €500,000 innovation initiative and the decision to award WPD Pharmaceuticals for novel antibody–drug conjugate programmes in oncology. He signals of the company’s intent to back differentiated science with execution.

The episode also addresses regulatory shifts in biosimilars and how reduced requirements can help expand patient access, alongside a broader discussion of operating in a more multipolar global environment. Gregor outlines why CDMOs must move beyond traditional fee-for-service delivery toward deeper partnership models that improve speed, quality, and reliability.

Fortunately, Poland remains one of the more cost-efficient countries within the EU. With the scientists we have in-house, there is no need for trial and error. We move directly in the right direction, which reduces costs and saves time.

Mabion combines specialised biologics expertise, quality-focused operations, and a partnership mindset. Our services are designed for programmes that requiring precision, transparency, and scalable delivery. We start with people, which is reinforced by scientific excellence and a clear commercial direction.

We are open to new client engagements globally. Mabion team welcome conversations with biotech and pharma teams seeking a CDMO partner for biologics, biosimilars, and advanced modalities.

Prepared by:

Jakub Knurek

Marketing Specialist

j.knurek@mabion.eu

Jakub Knurek

Marketing Specialist

Jakub Knurek is a marketing and business development expert specializing in CDMO operations with scientific and biopharmaceutical background. During the COVID-19 pandemic, he contributed to the development of the Novavax protein vaccine. As a side project, he runs his own pharma company.

As the author of numerous articles, he is recognized as an important voice of the younger generation of scientists. He is a member of Mabion’s representation at industry trade shows, including BIO International Convention 2025 in Boston, 2nd Global Biologics India 2025 in Hydrabad, CPHI 2024 in Milan, CPHI 2023 in Barcelona, Life Sciences Baltics 2023 in Vilnius. He actively participates in academic, business and industry discussions, such as the “Building the Future Pharma Workforce” panel at CPHI Milan 2024.

Sources and further reading

1. ARTO Talent channel. Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics. Making It In Manufacturing. 2026.